Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Moffitt Cancer Center and Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT), have announced a strategic partnership aimed at advancing cancer treatment. This collaboration combines Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms to accelerate the development of personalized cancer therapies.
Under the agreement, Moffitt will provide Fulgent with priority access to its clinical resources to expedite the advancement of Fulgent’s clinical pipeline. Fulgent's nanoencapsulation technology has already transformed paclitaxel into the soluble FID-007, showing substantial tumor reduction in Phase 1 studies.
The partnership will also co-develop next-generation personalized treatment options, leveraging Moffitt's scientific expertise and Fulgent's nano-particle-based drug development platform and genetic testing capabilities.
- Strategic partnership with Moffitt Cancer Center to advance cancer treatment.
- Priority access to Moffitt’s clinical expertise and resources for Fulgent Pharma.
- Fulgent’s FID-007 demonstrated substantial tumor reduction in Phase 1 clinical studies.
- Combination of Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms.
- Co-development of next-generation personalized cancer treatments.
- No specific financial terms or immediate revenue impacts disclosed.
- FID-007 is still in early Phase 1 clinical studies, indicating long development timelines.
- Clinical and business success of the partnership depends on future trial results and regulatory approvals.
Insights
The collaboration between Moffitt Cancer Center and Fulgent Pharma is poised to make significant strides in the field of cancer therapeutics. The integration of Moffitt's clinical expertise with Fulgent's nanobiotechnology capabilities has the potential to enhance the efficacy and precision of cancer treatments.
One key element is the use of Fulgent's nanoencapsulation technology, particularly its application to paclitaxel, which has traditionally suffered from poor solubility. Transforming this drug into a more soluble form for intravenous injection could mean better drug delivery and reduced side effects for patients.
From a clinical standpoint, this partnership is highly promising. The accelerated clinical trial activation and enhanced patient screening processes could lead to faster development and application of new treatments. This is especially critical in oncology, where time can often be a deciding factor in patient outcomes.
This partnership marks a significant step towards personalized medicine, especially in oncology. By combining Moffitt's extensive research capabilities and access to diverse tissue samples with Fulgent's cutting-edge genomics and nanoparticle drug development platforms, the scope for innovative treatment options is vast.
Importantly, the move to develop next-generation personalized treatments aligns with current trends in precision medicine, where therapies are tailored to the genetic and molecular profile of each patient. Such an approach can enhance the effectiveness of treatments and minimize adverse effects, leading to better patient outcomes.
The use of Fulgent's FID-007 in Phase 1 clinical studies showing substantial tumor reduction is a promising precursor to potential breakthroughs in various cancer treatments. If these results can be replicated in larger, more diverse patient populations, it could revolutionize cancer care.
From a financial perspective, this partnership between Moffitt Cancer Center and Fulgent Pharma could be highly beneficial for both entities. For Fulgent Genetics (NASDAQ: FLGT), this collaboration could accelerate the commercialization of its nanotherapeutics, potentially boosting revenue streams and investor confidence.
The priority access to Moffitt's clinical expertise and resources may shorten the time-to-market for Fulgent's drug candidates, which is a significant advantage in the highly competitive biotech sector. Faster clinical trial activation and data sharing are important for reducing development costs and improving the efficiency of bringing new drugs to market.
Furthermore, successful advancements in personalized cancer therapies through this partnership could enhance Fulgent's market position and lead to long-term financial growth. However, investors should consider the inherent risks in biotech investments, such as regulatory hurdles and the uncertainty of clinical trial outcomes.
Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine
Fulgent Pharma, a leader in nanoencapsulation technology, has transformed paclitaxel, a chemotherapy drug known for its poor solubility, into a soluble counterpart suitable for intravenous injection called FID-007. In Phase 1 clinical studies conducted with FID-007 to date, substantial tumor reduction across various cancer types, including breast, head and neck, lung, bile duct, and pancreatic cancers, has been observed.
Additionally, the partnership will focus on co-developing next-generation personalized treatment options for cancer. Moffitt will leverage its broad scientific and immunology expertise, access to tissue samples and nonclinical research resources, while Fulgent will contribute its novel and proprietary nano-particle-based drug development platform along with its broad spectrum genetic and genomic testing capabilities.
“Pooling our unique strengths, Moffitt and Fulgent will strive to create new precision oncology therapies customized to meet the specific needs of each patient, thereby improving future outcomes,” said Fulgent Pharma President and CSO Ray Yin, Ph.D.
“This partnership aligns with Moffitt’s mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients,” said Moffitt President and CEO Patrick Hwu, M.D.
“We are excited to collaborate with Moffitt Cancer Center, a global cancer research and treatment leader,” said Ming Hsieh, CEO of Fulgent Genetics. “By combining Moffitt’s clinical and research expertise with Fulgent’s innovative nanotherapeutic platform and growing patent portfolio, we believe we can make significant strides in advancing personalized cancer treatment options.”
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The
About Fulgent Pharma
Fulgent Pharma began as part of Fulgent LLC in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; Fulgent Pharma’s research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials, including any implication that interim or preliminary data will be representative of final results, the intended benefits of the collaboration, including whether the collaboration expedites development of any of Fulgent Pharma’s product candidates. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Fulgent Pharma’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on Fulgent Pharma’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the success of Fulgent Pharma’s development efforts, including its ability to progress its candidates through clinical trials on the timelines expected; its compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and its ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.
The forward-looking statements made in this press release speak only as of the date of this press release, and Fulgent Pharma and Fulgent Genetics assume no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.
Fulgent Genetics, Inc.’s reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514935253/en/
Patty Kim
Moffitt Cancer Center
813-745-7322
Patty.Kim@Moffitt.org
Melanie Solomon
The Blueshirt Group
melanie@blueshirtgroup.com
Source: Fulgent Pharma
FAQ
What is the recent partnership between Moffitt Cancer Center and Fulgent Pharma about?
Which company is collaborating with Moffitt Cancer Center according to the press release?
What will Fulgent Pharma gain from the partnership with Moffitt Cancer Center?
What is Fulgent Pharma's FID-007?
What focus areas are targeted in the Moffitt Cancer Center and Fulgent Pharma collaboration?
